PRKN and neoplasm: Multiple studies have documented tumor suppression mechanisms of Parkin activity, or mitophagy.[32] Therefore, targeting the disruption of PINK1‐PRKN‐mediated mitophagy may be a promising therapeutic strategy for ALK+ ALCL.